Growth Metrics

Calidi Biotherapeutics (CLDI) Accumulated Depreciation & Amortization (2024 - 2025)

Calidi Biotherapeutics' quarterly Accumulated Depreciation & Amortization came in at $1.8 million in Q4 2025, up 32.4% year-on-year from $1.4 million in Q4 2024, and up 4.79% quarter-over-quarter from $1.7 million in Q3 2025.

Calidi Biotherapeutics has reported Accumulated Depreciation & Amortization for 2 years, with the latest figure at $1.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 32.4% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (up 32.4% YoY), and the FY2025 full-year result was $1.8 million, up 32.4% from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 stood at $1.8 million, up from $1.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $1.8 million in Q4 2025, with the low at $1.4 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Calidi Biotherapeutics - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.79 Mn
Dec 31, 2025 1.79 Mn
Sep 30, 2025 1.71 Mn
Sep 30, 2025 1.71 Mn
Jun 30, 2025 1.61 Mn
Jun 30, 2025 1.61 Mn
Mar 31, 2025 1.47 Mn
Mar 31, 2025 1.47 Mn
Dec 31, 2024 1.36 Mn
Dec 31, 2024 1.36 Mn